Accordingly, thorough screening for subclinical hypertension of patients being considered for anti-TNF agent therapy and continuous monitoring may represent a therapeutic strategy to improve the safety of anti-TNF treatment that deserves further evaluation. This evidence concerns the gene TNF and Hypertension.